# US 10,758,609 B2 · Cross-reactive T-cell epitopes of HIV, SIV, and FIV for vaccines in humans and cats

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,758,609 B2
- Document ID: US10758609B2
- Status: Granted
- Kind: B2
- Application number: 15/762,108
- Filed: 2016-09-25
- Published: 2018-11-22
- Granted: 2020-09-01
- Earliest claimed: 2015-09-25
- Assignees: University of Florida Research Foundation, Inc.
- Applicants: University of Florida Research Foundation, Inc.
- Inventors: Janet K. Yamamoto
- Web page: https://patentgrep.com/patent/US10758609B2

## CPC

- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 39/12: Viral antigens
- A61P 31/14: for RNA viruses
- A61P 31/18: for HIV
- C07K 14/005: from viruses
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/572: {cytotoxic response}
- A61K 2039/575: {humoral response}
- A61K 2039/645: {Dendrimers; Multiple antigen peptides}
- C12N 2740/15034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/15071: Demonstrated in vivo effect
- C12N 2740/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16171: Demonstrated in vivo effect
- C12N 2740/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16271: Demonstrated in vivo effect
- C12N 2740/16334: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16371: Demonstrated in vivo effect
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The subject invention concerns methods and materials for inducing an immune response in an animal or person against an immunodeficiency virus, such as HIV, SIV, or FIV. In one embodiment, a method of the invention comprises administering one or more antigens and/or immunogens to the person or animal wherein the antigen and/or immunogen comprises one or more evolutionarily conserved epitopes of immunodeficiency viruses. In one embodiment, the epitope is one that is conserved between HIV and FIV.

## Claims

### Claim 1

A method for inducing an immune response in a person or animal against an immunodeficiency virus, comprising administering one or more antigens and/or immunogens to the person or animal, wherein said one or more antigens and/or immunogens comprise one or more evolutionarily conserved epitopes, wherein said epitopes are conserved between two or more different immunodeficiency viruses, and wherein said epitopes independently consist of the amino acid sequence of any of SEQ ID NOs: 1 to 37 or SEQ ID NOs:39 to 102.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said epitopes are conserved between HIV and FIV, or are conserved between HIV, SIV, and FIV.

### Claim 3 (depends on 1)

The method according to claim 1, wherein at least one of said epitopes is a T-cell epitope.

### Claim 4 (depends on 3)

The method according to claim 3, wherein said T cell epitope induces one or more T cell responses.

### Claim 5 (depends on 4)

The method according to claim 4, wherein said T cell response is production and/or release of cytotoxins, cytolysins, and/or cytokines.

### Claim 6 (depends on 1)

The method according to claim 1, wherein said induced immune response is a CTL-associated immune response and/or a T helper (Th) immune response.

### Claim 7 (depends on 1)

The method according to claim 1, wherein said induced immune response comprises induction of a CD4+ and/or CD8+ T cell response.

### Claim 8 (depends on 4)

The method according to claim 4, wherein said one or more antigens and/or immunogens are administered to said person or animal subcutaneously or intradermally.

### Claim 9 (depends on 5)

The method according to claim 5, wherein said cytotoxins, cytolysins, and/or cytokines are one or more of IL2, IFNγ, tumor necrosis factor α (TNFα), perforin, or granzyme A or B.

### Claim 10 (depends on 1)

The method according to claim 1, wherein said immune response is a protective immune response that provides protection against infection by said immunodeficiency virus.

### Claim 11 (depends on 1)

The method according to claim 1, wherein said epitopes independently consist of the amino acid sequence of any of SEQ ID NOs:26, 30, 35, or 88.

### Claim 12 (depends on 1)

The method according to claim 1, wherein said animal is a feline animal.

### Claim 13 (depends on 1)

The method according to claim 1, wherein said immunodeficiency virus is HIV or FIV.

### Claim 14 (depends on 1)

The method according to claim 1, wherein said epitopes are provided in a multiple antigenic peptide (MAP) construct.

### Claim 15 (depends on 1)

The method according to claim 1, wherein said antigens and/or immunogens are administered as a vaccine composition.

### Claim 16 (depends on 15)

The method according to claim 15, wherein said vaccine composition comprises a pharmaceutically-acceptable carrier, diluent, or adjuvant.

### Claim 17 (depends on 16)

The method according to claim 16, wherein said adjuvant is threonyl muramyl dipeptide (MDP), RIBI adjuvant system components including the cell wall skeleton (CWS) component, Freund's complete adjuvant, Freund's incomplete adjuvant, bacterial lipopolysaccharide (LPS), a cytokine, a lymphokine, or an interleukin, or any combination thereof.

### Claim 18 (depends on 17)

The method according to claim 17, wherein said cytokine is γ-IFN, GM-CSF, or CSF or said interleukin is IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, or IL-22.

### Claim 19 (depends on 1)

The method according to claim 1, wherein said epitopes independently consist of two or more of any of SEQ ID NOs: 1 to 37 or SEQ ID NOs: 39 to 102.

### Claim 20 (depends on 1)

The method according claim 1, wherein said epitopes independently consist of the amino acid sequence of any of SEQ ID NOs: 1, 3, 4, 5, 6, 8, 10, 12, 14, 15, 16, 17, 19, 20, 21, 22, 23, 26, 29, 30, 31, 32, 33, 34, 35, 36, 37, 52, 53, or 66.